Michel Chonchol, MD
Nephrology · Aurora, CONPI 1942390620
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,040 of the $2,860 with a category attached, or 71.3%. Otsuka Pharmaceutical Development & Commercialization, Inc. accounts for 92.1% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $2,061 and has fallen 98.3% since, to $34 in 2025.
Across 9 payments — averaging $317.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
- Otsuka America Pharmaceutical, Inc.$96
- AstraZeneca$76
- Amgen$34
- Vifor Pharma, Inc.$19
Across 32 payments — averaging $10,681 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kadmon Corporation LLC$145K
- Sanofi$116K
- OPKO Pharmaceuticals, LLC$46K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$34K
- Sanofi US Services Inc.$1K
What the payments were for
- Consulting fees$2,04071%
- Speaking & faculty fees$54819%
- Food & beverage$1776%
- Education$963%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $2,635 |
| Otsuka America Pharmaceutical, Inc. | 1 | $96 |
| AstraZeneca | 1 | $76 |
| Amgen | 1 | $34 |
| Vifor Pharma, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JYNARQUE$2,040
How this compares
$2,860 in reported general payments places this provider in the 75th percentile of 152 nephrology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Eplerenone | 14 | $1,623 |
| Amlodipine Besylate | 24 | $153 |
| Furosemide | 18 | $141 |
| Losartan Potassium | 16 | $118 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Aurora
- Richard JohnsonAurora$62K
- Bruce KaplanAurora$42K
- Sixto GiustiAurora$23K
- Isaac TeitelbaumAurora$22K
- Charles EdelsteinAurora$13K
- Judith BlaineAurora$9K
- Joshua ThurmanAurora$8K
- Neil ManekAurora$8K
- Gregory ProctorAurora$7K
- Moshe LeviAurora$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.